breast cancer
Conditions
Interventions
Observation Group:NA
Sponsors
Army Medical Center of PLA
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily join the study, sign informed consent, have good compliance and be willing to cooperate with follow-up; 2. Tumor biopsy confirmed HER2-positive breast cancer; 3. HER2-positive, unresectable locally advanced or metastatic breast cancer previously treated with anti-HER2 drugs and purple shirtanes. Patients include: prior treatment for locally advanced or metastatic disease or disease recurrence during completion of adjuvant therapy or within six months; 4. Plan to receive T-DM1 treatment; 5. ECOG score 0-1; 6. Female, older than 18 years old; 7. Willing to undergo tumor evaluation and blood sample collection during the study.
Exclusion criteria
Exclusion criteria: 1. Failure to sign informed consent; 2. Pregnant or lactating women; 3. The patient has severe concomitant medical conditions, or any other condition in which the investigator believes that the patient is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Real-world progression-free survival (rwPFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR);Disease Control Rate (DCR);Time to stop treatment (TTD);Duration of mitigation (DoR); | — |
Countries
China
Contacts
Public ContactYan Xu
Army Medical Center of PLA
Outcome results
None listed